Skip to main content

Evaluation of the efficacy and of the antiviral activity of T-705 (favipiravir) duringEbola virus infection in non-human primates humans

Objective

The ongoing Ebola outbreak in West Africa is the largest and deadliest the world has ever seen. In September 2014, the number of EBOV cases exceeded the total of all cases from previous known outbreaks. Further, this public health crisis shifted into a complex emergency, with significant, social, economic, humanitarian, political and security dimensions. Till date, no effective medicine has been proven to be effective against EBOV. As a result, it is immensely difficult to mitigate the current outbreak as well as prevent further outbreaks in this region. On Sept 4-5 2014, the WHO gathered expertise on experimental therapies and vaccines and their role in containing the Ebola outbreak in West Africa. During this consultation, experts identified several therapeutic and vaccine interventions that should be the focus of priority evaluation. Among these candidates is the existing antiviral drug Favipiravir, that has proven activity against many RNA viruses in vivo and in vitro including Ebola. Favipiravir is known to inhibit viral gene replication within infected cells to prevent propagation among which it inhibits viral gene replication within infected cells to prevent propagation. Hence, Favipiravir is currently aimed as a curative option in severe pandemic flue. Furthermore, there is currently enough stock of Favipiravir to even treat more than 20.000 patients, and the producer of Favipiravir, Toyoma Chemical/Fujifilm in Japan is willing to rapidly upscale the production of this drug. This drug has been extensively tested in humans and approved in Japan for treatment and prevention of influenza. The drug has shown an excellent safety profile in more than 2000 patients tested and no major adverse effect were reported. The current crisis requires both an immediate response to treat patients and prevent the further spread of the epidemic, as well as long term commitment in the complex sociocultural context. REACTION! will address both needs.

Call for proposal

H2020-Adhoc-2014-20
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Address
Rue De Tolbiac 101
75654 Paris
France
Activity type
Research Organisations
EU contribution
€ 1 240 726

Participants (12)

ASSOCIATION POUR LE DEVELOPPEMENT DE L'ENSEIGNEMENT ET DES RECHERCHES AUPRES DES UNIVERSITES, DES CENTRES DE RECHERCHE ET DES ENTREPRISES D'AQUITAINE
France
EU contribution
€ 477 262
Address
Avenue Du Docteur Albert Schweitzer - Centre Condorcet 162
33608 Pessac
Activity type
Research Organisations
BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN
Germany
EU contribution
€ 64 250
Address
Bernhard Nocht Strasse 74
20359 Hamburg
Activity type
Research Organisations
INSTITUT PASTEUR
France
EU contribution
€ 74 025
Address
Rue Du Docteur Roux 25-28
75724 Paris Cedex 15
Activity type
Research Organisations
ECOLE NORMALE SUPERIEURE DE LYON
France
EU contribution
€ 142 500
Address
Parvis Rene Descartes 15
69342 Lyon
Activity type
Higher or Secondary Education Establishments
UNIVERSITE D'AIX MARSEILLE
France
EU contribution
€ 88 500
Address
Boulevard Charles Livon 58
13284 Marseille
Activity type
Higher or Secondary Education Establishments
RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
Germany
EU contribution
€ 86 250
Address
Seminarstrasse 2
69117 Heidelberg
Activity type
Higher or Secondary Education Establishments
DRUG DISCOVERY FACTORY BV
Netherlands
EU contribution
€ 127 062,50
Address
Joop Geesinkweg 167
1114 AB Amsterdam Duivendrecht
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UNIVERSITEIT VAN AMSTERDAM

Participation ended

Netherlands
EU contribution
€ 72 359
Address
Spui 21
1012WX Amsterdam
Activity type
Higher or Secondary Education Establishments
UNIVERSITEIT UTRECHT
Netherlands
EU contribution
€ 4 250
Address
Heidelberglaan 8
3584 CS Utrecht
Activity type
Higher or Secondary Education Establishments
UNIVERSITE CHEIKH ANTA DIOP DE DAKAR
Senegal
EU contribution
€ 134 375
Address
Avenue Martin Luther King
- Dakar Fann
Activity type
Higher or Secondary Education Establishments
Department of Health
United Kingdom
EU contribution
€ 64 250
Address
Quarry House, Quarry Hill
LS2 7UE Leeds
Activity type
Research Organisations
FONDATION POUR L INSTITUT DE HAUTES ETUDES INTERNATIONALES ET DU DEVELOPPEMENT
Switzerland
EU contribution
€ 0
Address
Maison De La Paix Chemin Eugene Rigot 2
1202 Geneve
Activity type
Higher or Secondary Education Establishments